Quellenübersicht

DOG-Report in Ophthalmo Chirurgie, Ausgabe: 06/2025 (Veröffentlichung am 27.11.2025):

  1. Im JHB, et al. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis. Surv Ophthalmol 2022; 67:1244-1251.
  2. Teo ZL, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology 2021; 128(11):1580–1591.
  3. Rübsam A, et al. Role of Inflammation in Diabetic Retinopathy. Int J Mol Sci 2018;19(4):942.
  4. Romero-Aroca et al. Pathophysiology: Vasogenic versus Inflammatory. J of Diab Res 2016.
  5. Reichenbach A et al. “Müller cells as players in retinal degeneration and edema.” Graefe”s Arch Clin Exp Ophthalmol. 2007; 245, 627–636.
  6. FAME Study group. Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at least 3 Years in Patients with Diabetic Macular Edema. Ophthalmology 2012;119:2125-32.
  7. Khoramnia et al. Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN®): 3-year results from the European IRISS registry study. BJO 2023;107:1502-1508 2022.
  8. Riemann CD, et al. Reduction in Retinal Thickness Fluctuations After Treatment With Fluocinolone Acetonide Implant for DME: A Post-Hoc Analysis of the USER Study. Ophthalmic Surgery, Lasers and Imaging Retina. 2020;51(5):298-306.
  9. Sivaprasad S, et al. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939-46.
  10. Ziemssen F, et al. “DR Barometer- Shifting the needle” EURETINA Abstracts 2023.
  11. Saedon H, et al. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol 2017;36:343-346.
  12. Kaiserman et al, Dry eye in diabetic patients., Am J Ophthalmol 2005; 139 498-503.
  13. Gonzalez VH, et al. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Am J Ophthalmol 2016;172:72-79.
  14. Augustin A, et al. Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper. Klin Monbl Augenheilkd 2021;238:73-84.
  15. Schmidt-Erfurth U, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017;237:185-222.
  16. Boscia F et al. Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data. Eur J Ophthalmol 2024; 1:1120671214123679.
  17. Taloni A et al. Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema. Patient Prefer Adherence 2023; 17: 3307-3329.
  18. Salvetat ML et al. Emerging biomarkers in diabetic macular edema: structural and functional correlation. J Clin Med 2024; 13: 1327.
  19. Munk MR, et al. Retinal layer segmentation in diabetic macular edema: repeatability and clinical relevance. Int J Mol Sci. 2022;23:7585.
  20. Udaondo P, et al. Disorganization of the retinal inner layers as a predictor of visual outcome in diabetic macular edema. Clin Ophthalmol. 2021;15:3183-3191.
  21. Vitiello L, et al. The role of retinal biomarkers in predicting response to therapy in diabetic macular edema. Life. 2024;14:725.
  22. Markan A et al. Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema. Ther Adv Ophthalmol. 2020; 12:2515841420950513.
  23. Lee H, et al. Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina 2016; 36: 1372-1380.
  24. Sonoda S, et al. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina. 2014;34:741-748.

Stand: Oktober 2025 I DE-ILV-MMM-0890

Anzeige in Diabetes aktuell, Ausgabe: 07/2025 (Veröffentlichung am 14.11.2025):

  1. Singh P et al. Int Med Case Rep 2018; 11: 265-269.
  2. Singer M et al. Ophthalmology 2022; 129(6): 605-613.
  3. Khoramnia R et al. Br J Ophthalmol 2022; 0: 1-7.
  4. Campochiaro PA et al. Ophthalmology 2011 Apr; 118 (4): 626-635.e2.
  5. Abu Arif J et al. Biomedicines 2024; 12, 1106.

Stand: Oktober 2025 I DE-ILV-MMM-0891

Newsletter Ophthalmologische Nachrichten (Veröffentlichung am 14.10.2025):

  1. Singh P et al. Int Med Case Rep 2018; 11: 265-269.
  2. Singer M et al. Ophthalmology 2022; 129(6): 605-613.
  3. Khoramnia R et al. Br J Ophthalmol 2022; 0: 1-7.
  4. Campochiaro PA et al. Ophthalmology 2011 Apr; 118 (4): 626-635.e2.
  5. Abu Arif J et al. Biomedicines 2024; 12, 1106.
  6. ILUVIEN® Fachinformation, Stand: August 2024.

Stand: Oktober 2025 I DE-ILV-MMM-0882

Concept Ophthalmologie DOG-Kongressnewsletter (Veröffentlichung im September 2025):

  1. Singh P et al. Int Med Case Rep 2018; 11: 265-269.
  2. Singer M et al. Ophthalmology 2022; 129(6): 605-613.
  3. Khoramnia R et al. Br J Ophthalmol 2022; 0: 1-7.
  4. Campochiaro PA et al. Ophthalmology 2011 Apr; 118 (4): 626-635.e2.
  5. Abu Arif J et al. Biomedicines 2024; 12, 1106.
  6. ILUVIEN® Fachinformation, Stand: August 2024.
  7. Jaffe GJ et al. Ophthalmogy 2020; 1-11.
  8. Weber LF et al. J Ophthal Inflamm Infect (2019); 9:3.
  9. Hikal M et al. J Clin Med 2021; 10, 3966.

Stand: September 2025 I DE-ILV-MMM-0878

ZPA-Report vom DOC-Symposium (Veröffentlichung im September 2025):

  1. Pleyer U et al. Journal of Ophthalmic Inflammation and Infection. 2024;14:22.
  2. ILUVIEN® Fachinformation, Stand: August 2024.
  3. OZURDEX® Fachinformation, Stand: Juni 2024.
  4. Jaffe GJ et al. Ophthalmology 2020;127:1395-1404.
  5. Christensen L et al., Ocular Immunology & Inflammation 2024; 33, 683–694.
  6. Buhl L et al., Ocular Immunology and Inflammation 2024; doi: 10.1080/09273948.2023.2250431.
  7. Lardenoye, C et al. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006, 113, 1446–1449.
  8. Thurau, SR. Cystoid macular edema in uveitis. Ophthalmologe 2005; 102:485–490.
  9. Hikal M et al., J Clin Med 2021; 10:3966.
  10. Logeswaran A et al., Ocul Immunol Inflamm. 2024.
  11. Bodaghi et al. J Ophthal Inflamm Infect 2020;10:32.
  12. Abu Arif J, et al. Biomedicines. 2024; 12:1106.
  13. Jabs DA, Busingye J. Am J Ophthalmol 2013;156:228–36.
  14. Barisani-Asenbauer et al. Orphanet J Rare Dis 2012;7:57.
  15. Gordon MO, et al. Arch Ophthalmol. 2002;120:714–720.
  16. https://www.aao.org/education/interactive-tool/risk-calculators-primary-open-angle-glaucoma (Zugriff: Mai 2025).
  17. Singer MA, et al. Ophthalmology 2022;129:605–13.
  18. Campochiaro PA, et al. Ophthalmology. 2012;119:2125e2132.16.
  19. Khoramnia R, et al. Br J Ophthalmol 2023;107:1502-1508.
  20. Augustin AJ, et al. Eur J Ophthalmol 2020;30:382–91.
  21. Goñi FJ, et al. Ophthalmol Ther. 2016 Jun;5:47-61.

Stand: Juni 2025 I DE-ILV-MMM-0858

Eyefox-Sondernewsletter „Biomarker bei Uveitis“ vom 07.11.2024:

  1. Jaffe GJ et al. Ophthalmology 2020; 1-11.
  2. ILUVIEN® Fachinformation, Stand: August 2024, EINFACH – Applikatordesign, VERLÄSSLICH – Kontinuierliche Mikrodosierung, WIRKSAM – ILUVIEN®Fachinformation, Stand: August 2024.
  3. Buhl L et al. Ocul Immunol Inflamm. 2023: 1-5.
  4. Moll-Udina A et al. Int Ophthalmol 2023; 43(11): 4181-4195.
  5. Studsgaard A et al. Arch Clin Exp Ophthalmol. 2022; 260(5): 1633-1639.
  6. Alimera Sciences EU-Webinar: “International Long-Term Real-World Experiences of Using Local Therapies in NIU-PS: Sharing Perls of Wisdom” (20.06.2023):https://vimeo.com/992741281/b4b90aab11?share=copy.

Stand: November 2024 I DE-ILV-MMM-0807

ZPA-Report vom DOC-Symposium (Veröffentlichung im Oktober 2024):

  1. Zheng Y, et al. Indian J Ophthalmol 2012; 60: 428-31.
  2. CDC. National Diabetes Fact Sheet: https://www.cdc.gov/diabetes/php/data-research/index.html Letzter Zugriff Juli 2024.
  3. Bressler NM et al. JAMA Ophthalmol. 2018; 136: 257-269.
  4. Chakravarthy U et al. Br J Ophthalmol. 2018. pii: bjophthalmol-2018-312284.
  5. Khoramnia R et al. British Journal of Ophthalmology 2023; 107: 1502-1508.
  6. Augustin A et al. Eur J Ophthalmol. 2020 Mar; 30(2): 382-391.
  7. Rehak M et al. IOVS 2009; 50: 2359-2367.
  8. Rehak M et al. Graefes Arch Clin Exp Ophth.2011; 249: 1175-1183.
  9. Sivaprasad S et al. The impact of injection therapy on retinal patients with DME or RVO. Journal of Clinical Ophthalmology, 2016;10: 939-946.
  10. Sivaprasad S et al. The impact of injection therapy on retinal patients with DME or RVO. Journal of Clinical Ophthalmology, 2016; 10: 939-946.
  11. Schmidt-Erfurth U et al. Ophthalmologica 2017; 237(4): 185-222.
  12. Kersey JP & Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006 Vol 20, 407–416.

Stand: August 2024 I DE-ILV-MMM-0786

Eyefox-Sondernewsletter „Netzhaut“ vom 01.08.2024:

  1. Singer M et al. Ophthalmology 2022; 129(6):605-613.
  2. Singh P et al. Int Med Case Rep 2018; 11:265-269.
  3. Khoramnia R et al. Br J Ophthalmol 2022; 0: 1-7.
  4. Campochiaro PA et al. Ophthalmology 2012; 119: 2125-2132.
  5. ILUVIEN® Fachinformation, Stand: August 2024.
  6. Cunha Vaz et al. Ophthalmology 2014; Okt: 121(10): 1892-903.
  7. EINFACH – Applikatordesign, VERLÄSSLICH – Kontinuierliche Mikrodosierung, WIRKSAM – ILUVIEN® Fachinformation, Stand: August 2024.

Stand: Juli 2024 I DE-ILV-MMM-0777

Eyefox-Sondernewsletter „Biosimilars in der Ophthalmologie“ vom 04.07.2024:

  1. Singer M et al. Ophthalmology 2022; 129(6):605-613.
  2. Singh P et al. Int Med Case Rep 2018; 11:265-269.
  3. Khoramnia R et al. Br J Ophthalmol 2022; 0: 1-7.
  4. Campochiaro PA et al. Ophthalmology 2011 Apr; 118(4): 626-635.e2.

Stand: Juni 2024 I DE-ILV-MMM-0775

Technik-Report „10 Jahre ILUVIEN – 10 Jahre Erfahrung mit dem Fluocinolonacetonid-Implantat“:

  1. Grajewski R. Optionen in der Gegenwart: Überblick über aktuelle Uveitis-Therapien. 2022 Mar; Slide 18
  2. Jaffe et al. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis. Three-Year Results; Ophthalmology 2020; https://doi.org/10.1016/j.ophtha.2020.04.001
  3. Hutton D. PALADIN Study: Improved visual acuity, CST resulting from fluocinolone acetonide intravitreal implant. Ophthalmology Times Europe; 2022 Feb; PALADIN Study: Improved visual acuity, CST resulting from fluocinolone acetonide intravitreal implant (ophthalmologytimes.com). https://europe.ophthalmologytimes.com/view/paladin-study-improved-visual-acuity-cst-resulting-from-fluocinolone-acetonide-intravitreal-implant
  4. Gonzalez et al. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Am J Ophthalmol. 2016 Dec;172:72-79. doi: 10.1016/j.ajo.2016.09.012.
  5. Singer, M et al. 2022. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study. Ophthalmology

*im Vergleich zum Dexamethason-Implantat

Stand: November 2022 I DE-ILV-MMM-0665